HomeStartups Orgenesis lifecycle

Claimed by owner Last Update Jul 2, 2025 Suggest Edits Claim Profile

Claimed by owner

Orgenesis

Cell & Gene Therapy

PUBLIC on NASDAQ on Mar, 2018

Orgenesis

Orgenesis Overview

Cumulative Funding Raised Over Time ($)

Employees Over Time

Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies

#Acquisition #Partners

Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies

#Acquisition #Partners

Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings

#Investment

Orgenesis Provides Third Quarter 2024 Business Update

#Partners #Expand

Orgenesis Commences Trading on OTCQX® Best Market

#Public Trading #Partners

Orgenesis Announces Reverse Stock Split

#Public Trading

Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

#Partners #Expand

Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

#Partners #Investment #Expand

Orgenesis Provides Second Quarter 2024 Business Update

#Acquisition #Expand

Orgenesis Provides Business Update for the First Quarter of 2024

#Partners #Acquisition #Investment

Orgenesis Provides Year End Business Update

#Investment #Acquisition #Partners

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

#Partners

Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference

#Management Changes

Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes

#Investment #Partners

Orgenesis Inc. Announces $2.3 Million Private Placement

#Investment

Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing

#Investment #Partners #Expand

EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic

#Acquisition

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

#Acquisition #Management Changes

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

#Acquisition

EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic

#Acquisition

Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon

#Investment

Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM

#Customers #Partners

Orgenesis Provides Business Update for the Third Quarter of 2023

#Partners #Expand

Orgenesis Provides Business Update for the Third Quarter of 2023

#Partners

Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering

#Investment

Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding

#Partners #Investment #Expand

Orgenesis Announces Withdrawal of Proposed Public Offering

#Public Trading

Orgenesis Announces Proposed Underwritten Public Offering

#Public Trading #Investment

CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States

#Partners #Expand

Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

#Management Changes #Expand

Is Orgenesis (ORGS) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

#Investment

Orgenesis Inc (ORGS): A Deep Dive into Its Performance Potential

#Financial Strength #Profitability

Orgenesis (ORGS): A Value Trap in Disguise?

#Investment

Q2 2023 Orgenesis Inc Earnings Call

#Investment #Expand

Orgenesis Provides Business Update for Second Quarter of 2023

#Investment #Partners

Orgenesis Schedules Second Quarter 2023 Business Update Conference Call

#Management Changes

Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

#Management Changes

Orgenesis Announces Name Change of Morgenesis Business Unit to Octomera

#Investment #Partners

Orgenesis Inc. (NASDAQ:ORGS) On The Verge Of Breaking Even

#Investment

Orgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout California

#Partners #Customers

Claudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of Orgenesis

#Partners

Orgenesis Academy Graduates First Class of Cell and Gene Therapy Experts from theraCell Laboratories-backed Master’s Program

#Expand

Orgenesis to Participate in Benchmark’s 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023

#Partners

Orgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors

#Partners

Orgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare Strategy

Orgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service Subsidiary

Orgenesis CEO Vered Caplan Featured in Keynote Series at INTERPHEX Conference to Discuss Innovations in Cell & Gene Therapy Manufacturing

Orgenesis Inc.'s (NASDAQ:ORGS) Share Price Is Matching Sentiment Around Its Revenues

Orgenesis Inc. (NASDAQ:ORGS) Q4 2022 Earnings Call Transcript

Q4 2022 Orgenesis Inc Earnings Call

Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022

Orgenesis and UC Davis partner on decentralized development and manufacturing of CGTs

#Partners #Expand

Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call

Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California

Orgenesis Inc. Announces Closing of $3.7 Million Registered Direct Offering

Orgenesis Inc. Announces Pricing of $3.7 Million Registered Direct Offering

Investors in Orgenesis (NASDAQ:ORGS) have unfortunately lost 73% over the last five years

Orgenesis and Kurve Therapeutics Announce Pre-Clinical Study Results for a Cell-Based Oncolytic Virus Bearing Product Demonstrating Over 50% Reduction in a Murine Glioblastoma Model

Orgenesis Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Loss-Making Orgenesis Inc. (NASDAQ:ORGS) Expected To Breakeven In The Medium-Term

https://www.proactiveinvestors.com/companies/news/935582/orgenesis-leads-the-charge-at-an-exciting-time-for-cell-and-gene-therapy-935582.html

Orgenesis CEO talks disruption: 'We are the Uber of the cell and gene therapy space'

#Customers #Partners #Investment

Orgenesis teams up with Johns Hopkins University to develop gene therapies with its POCare platform

Orgenesis Granted FDA Orphan Drug Designation for Autologous Insulin Producing Cells in the Treatment of Severe Hypoglycemia-Prone Diabetes Resulting from Total Pancreatectomy

#Customers #Partners

Orgenesis Announces Planned Study to Confirm Suitability of Liver Cells as a Source for Personalized Cell Replacement Therapy for Insulin-Dependent Diabetic Patients

#Customers

Orgenesis Announces Collaboration Agreement with Columbia University to Develop Cellular Vaccination Product Platform for Pancreatic, Hepatic and Cholangiocarcinoma Cancers

#Partners

Orgenesis Announces Collaboration and License Agreement for Exosome-Related Technologies with ExcellaBio

#Partners

Orgenesis Announces Collaboration with Digilab to Develop Industrial 3D Printing Capability for Cellular Structures and Tissues for Clinical Use

#Partners

Orgenesis Announces Publication of an Independent Study "The Role of The Vasculature Niche on Insulin Producing Cells Generated by Transdifferentiation of Adult Human Liver Cells" in the Stem Cell Research and Therapy Journal

#Customers

Orgenesis Signs Master Service and Joint Venture Agreement with TheraCell Advanced Biotechnology for the Development of Cell and Gene Therapies

#Partners

Orgenesis Subsidiary Masthercell Global Announces Plans to Establish New Facility for Cell and Gene Therapy Commercial Manufacturing

#Expand

Orgenesis Announces the Opening of New Offices and Laboratories at Accessia Pharma in Liège, Belgium to Support its Point of Care Cellular Therapy Platform

#Partners #Expand

Orgenesis Announces U.S. Expansion of Masthercell Global Subsidiary

#Expand

Orgenesis Subsidiary Atvio Biotech to Present at Phacilitate Leaders World 2019 Conference

#Partners

Orgenesis CEO Selected to Participate in Cell and Gene Therapy Workshop at Biotech Showcase 2019 in California

#Investment

Orgenesis Announces Collaboration with MangoGen Pharma for Advanced Gene Delivery Platform

#Investment

https://www.proactiveinvestors.com/companies/news/211072/orgenesis-seals-pact-with-ben-gurion-university-to-develop-dissolvable-carriers-for-cell-culturing-211072.html

Orgenesis CEO says companies looking for ways to get costs of medicine down

Orgenesis optimistic that Hemogenyx deal will 'transform bone marrow transplantation'

#Partners

Orgenesis Announces Collaboration with Ben-Gurion University to Develop and Commercialize a Novel Scaffold Technology for Cell Transplantation

#Partners #Investment

Orgenesis Appoints Professor Lorenzo Piemonti to Scientific Advisory Board

#Partners

Israeli cell therapy co Orgenesis raises $10m

#Investment #Acquisition

Orgenesis receives €2.015 million grant to develop potential cure for Type 1 Diabetes

#Investment

How Orgenesis Hopes To Cure Type 1 Diabetes

#Investment #Expand

New diabetes treatment would turn liver cells into insulin-producers

#Customers #Partners #Investment #Expand

Similar Companies

Driven by Finder AI

Primary sector

Total funding

Undisclosed

Funding stage

undefined

Number of employees

Founded

1/2008

Team Members

undefined

Contact Team

Affiliated Organizations

(undefined)

Locations

Israel

Photos & videos

(0)

No Data, yet.

Sorry, no content found under this section.

Orgenesis Business

Business models

Product stage

Geographic markets

Products

Sector

Primary:

Target Customer

Core Technology

Orgenesis Financials

Total funding Undisclosed

Market cap Undisclosed

Last funding Undisclosed

Funding stage undefined

Total rounds undefined

Investors undefined

Cumulative Funding Raised Over Time ($)

Public Offerings & Exits

Initial Public Offering EXIT

Undisclosed

Mar 2018

Stock Exchange

NASDAQ

Valuation Undisclosed

Undisclosed

Private Equity Funding

Debt Financing

$10M

Dec 2015

$10M

Undisclosed Round

$3M

Dec 2013

1 Investors

$3M

Non-Equity Funding

Grant

$12.8M

Feb 2017

1 Grantors

$12.8M

Grant

$2.4M

Nov 2014

1 Grantors

$2.4M

Mergers and Acquisitions

M&A

Undisclosed

Mar 2025

Type Acquisition

Acquired

Neurocords

Undisclosed

M&A

Undisclosed

Sep 2020

Type Acquisition

Acquired

Koligo Therapeutics

Undisclosed

M&A

Undisclosed

Apr 2020

Type Acquisition

Acquired

Tamir Biotechnology

Undisclosed

Orgenesis Lifecycle

Cumulative Funding Raised Over Time ($)

Timeline

Employees Over Time

News Over Time

Type Acquisition

Acquired

Neurocords

Undisclosed

Type Acquisition

Acquired

Koligo Therapeutics

Undisclosed

Type Acquisition

Acquired

Tamir Biotechnology

Undisclosed

Stock Exchange

NASDAQ

Valuation Undisclosed

Undisclosed

1 Investors

$12.8M

Debt Financing

$10M

Dec 2015

$10M

1 Investors

$2.4M

Undisclosed Round

$3M

Dec 2013

1 Investors

$3M

News Over Time

News Articles